The FTO gene, commonly known as the "fat mass and obesity-associated gene," has been extensively studied for its role in obesity and metabolic health. Regarding its connection with VO2 peak or cardiorespiratory fitness, especially in the context of cancer, the research is still evolving. Here are some key points to consider:
1. **FTO and Obesity**: The FTO gene is known to influence body mass and obesity risk, which indirectly affects cardiorespiratory fitness. Individuals with certain variants of the FTO gene might have a predisposition to higher body mass, potentially leading to lower VO2 peak values.
2. **FTO and Exercise Response**: Some studies suggest that the FTO gene might affect how individuals respond to exercise in terms of weight loss and improvements in fitness levels, including VO2 peak. However, this area of research is still developing, and findings are not conclusive.
3. **Cancer Risk**: There is research indicating that certain variants of the FTO gene might be associated with an increased risk of certain types of cancer. Obesity is a well-known risk factor for several types of cancer, and the FTO gene plays a role in obesity.
4. **Exercise, FTO, and Cancer Outcomes**: For cancer patients, exercise has been shown to improve outcomes and quality of life. Whether the FTO gene affects the efficacy of exercise interventions in cancer patients, including improvements in VO2 peak, is an area that warrants further research.
5. **Personalized Medicine**: Understanding the role of genes like FTO in diseases like cancer and in physical fitness parameters such as VO2 peak could lead to more personalized medicine approaches. Tailoring exercise and treatment strategies based on genetic makeup could potentially improve outcomes.
In summary, while there is a clear link between the FTO gene, obesity, and potentially cancer risk, its direct connection to VO2 peak in the context of cancer is less clear and is an area of ongoing research. The interplay between genetics, physical fitness, and cancer is complex and subject to a wide range of individual variability.
- Forums
- ASX - By Stock
- Ann: Bonus Options Prospectus
The FTO gene, commonly known as the "fat mass and...
-
-
- There are more pages in this discussion • 127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.47 |
Change
-0.055(3.61%) |
Mkt cap ! $250.5M |
Open | High | Low | Value | Volume |
$1.53 | $1.58 | $1.46 | $143.9K | 96.36K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 230 | $1.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.48 | 550 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 230 | 1.465 |
1 | 410 | 1.460 |
3 | 46800 | 1.450 |
2 | 25548 | 1.440 |
1 | 2046 | 1.420 |
Price($) | Vol. | No. |
---|---|---|
1.480 | 550 | 1 |
1.490 | 2470 | 1 |
1.535 | 2456 | 2 |
1.570 | 37690 | 1 |
1.575 | 2000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, MD & CEO
Charles Armstrong
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online